Partnering

PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, has signed an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm…

Immunovaccine, a Nova Scotia, Canada-headquartered clinical-stage immunotherapy and vaccine company, is expanding its collaboration with Leidos, a science and technology company, to develop preventative, peptide-based malaria vaccine candidates. The United…

Biogen and Alkermes have signed a license and collaboration agreement to develop and commercialize ALKS 8700, an oral, monomethyl fumarate small-drug molecule in Phase III development for treating relapsing forms…

Merck & Co. and Cue Biopharma, a Cambridge, Massachusetts-headquartered immunotherapy company, have signed a research collaboration and license agreement in a deal worth up to $374 million. Under the deal,…

Bayer has signed an agreement with Loxo Oncology, a Stamford, Connecticut-based biopharmaceutical company, to develop Loxo’s larotrectinib (LOXO-101) and LOXO-195 for treating patients with cancers harboring tropomyosin receptor kinase (TRK)…

Takeda Pharmaceutical Company and Portal Instruments, a Cambridge, Massachusetts-based medical equipment manufacturer, have agreed to develop and commercialize Portal’s needle-free drug delivery device for potential use with Takeda’s investigational or…

Pfizer and Spark Therapeutics, a Philadelphia, Pennsylvania-headquartered biopharmaceutical company, have amended their license agreement for SPK-9001, an investigational gene therapy for hemophilia B. In December 2014, Pfizer signed an agreement…

Novartis and Homology Medicines, a Bedford, Massachusetts-based genetic medicines company focused on gene-editing and gene-therapy technology, have agreed to use Homology’s proprietary gene-editing technology to develop new treatments for select…

Janssen Biotech, one of the pharmaceutical companies of Johnson & Johnson, has signed a license agreement worth up to $1.4 billion with Zymeworks, a Vancouver, Canada-headquartered clinical-stage biopharmaceutical company. Under…

Sanofi has partnered with Principia Biopharma, a South San Francisco, California-based clinical-stage biopharmaceutical company, to develop an experimental oral treatment for multiple sclerosis (MS) and other potential treatments for central…